The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022

卷:257

Review

关键词: COVALENT INHIBITORS;    GENOME SEQUENCE;    ACHILLES-HEEL;    CORONAVIRUS;    DISCOVERY;    EBSELEN;    IDENTIFICATION;    REPLICATION;    DESIGN;    3C;   

DOI  :  10.1016/j.ejmech.2023.115491

来源: SCIE

【 摘 要 】

The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (Mpro) of SARS-CoV-2 plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-19. Many SARS-CoV-2 Mpro inhibitors have been reported, including covalent and noncovalent inhibitors. The SARS-CoV-2 Mpro inhibitor PF-07321332 (Nirmatrelvir) designed by Pfizer has been put on the market. This paper briefly introduces the structural characteristics of SARS-CoV-2 Mpro and summarizes the research progress of SARS-CoV-2 Mpro inhibitors from the aspects of drug repurposing and drug design. These information will provide a basis for the drug development of treating the infection of SARS-CoV-2 and even other coronaviruses in the future.

【 授权许可】

Free